12:00 AM
Aug 31, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Diamyd diabetes vaccine: Phase III amended

Next month, the company will expand enrollment to patients ages 10-16 in an ongoing, double-blind, placebo-controlled, U.S. Phase III trial evaluating subcutaneous Diamyd diabetes vaccine in...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >